HCPCS Level II code Q5100 denotes the biosimilar product ustekinumab-kfce (Yesintek), billed per 1 mg unit for parenteral administration. As a biosimilar to ustekinumab, this code facilitates billing for the medication itself rather than the administration procedure, which is typically reported separately. Nationally, biologic and biosimilar billing codes like Q5100 matter because they affect formularies, payer coverage policies, and cost management strategies for chronic immune-mediated conditions treated with ustekinumab-class agents.

Key payers covered in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise overview of the code’s clinical role, typical sites of service, and the payer landscape relevant to coverage and billing. The publication summarizes benchmarks where available, notes recent policy updates affecting biosimilar adoption, and provides clinical context about the medication class and billing implications. Where specific payer or clinical detail is not present in the source input, the report notes that data is not available in the input.